General
Oxford-AstraZeneca vaccine shows promise in elderly, trial results by Christmas
Oxford University and AstraZeneca’s potential COVID-19 vaccine produced a strong immune response in older adults, newly published data has showed, with researchers expecting to release late-stage trial results by Christmas.
Key points:
- Late stage Oxford-AstraZeneca trials have shown it develops antibody and T-cell responses in elderly patients
- Rival drugmakers Pfizer-BioNTech and Moderna have recently pushed ahead in the race for a COVID vaccine
- Researchers report no serious side effects from the Oxford-AstraZeneca vaccine
The data, reported in part last month but published in full in The Lancet medical journal on Thursday, suggest that those aged over 70, who are at higher risk of serious illness and death from COVID-19, could build robust…
Continue Reading
-
General20 hours agoStar Wars’ fascist dystopia has never felt closer than in new season of Andor
-
Business17 hours ago10 high-conviction ASX dividend shares to buy for passive income today
-
General23 hours agoCoalition to chart path forward as family feud cooled
-
Noosa News23 hours agoInterest rates: Why we will keep paying the same repayments